AR019256A1 - USE OF TETRACICLE DERIVATIVES [6-6-2-0 (2.27) .0 (9.14)] HEXADECA-2 (7), 3, 5, 9 (14), 10,12-HEXAENE, FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS CONACTION PHOSPHOLIPASE INHIBITORY, DERIVATIVE REFERRALS AND PHARMACEUTICAL PREPARATION CONTAINING AT LEAST ONE OF SUCH DERIVATIVES - Google Patents
USE OF TETRACICLE DERIVATIVES [6-6-2-0 (2.27) .0 (9.14)] HEXADECA-2 (7), 3, 5, 9 (14), 10,12-HEXAENE, FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS CONACTION PHOSPHOLIPASE INHIBITORY, DERIVATIVE REFERRALS AND PHARMACEUTICAL PREPARATION CONTAINING AT LEAST ONE OF SUCH DERIVATIVESInfo
- Publication number
- AR019256A1 AR019256A1 ARP980104764A ARP980104764A AR019256A1 AR 019256 A1 AR019256 A1 AR 019256A1 AR P980104764 A ARP980104764 A AR P980104764A AR P980104764 A ARP980104764 A AR P980104764A AR 019256 A1 AR019256 A1 AR 019256A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- derivatives
- formula
- pharmaceutical preparations
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/31—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by at least three rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
- C07C259/16—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/22—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/86—Ring systems containing bridged rings containing four rings
- C07C2603/88—Ethanoanthracenes; Hydrogenated ethanoanthracenes
Abstract
Utilizacion de derivados tetraciclo[6.6.2.0(2.7).0(9.14)]-hexadeca-2(7), 3, 5, 9, (14), 10, 12-hexaeno de formula (1): caracterizado porque: R1 y R2 soniguales o diferentes y significan hidrogeno o un átomo de halogeno, X simboliza hidrogeno e Ysimb oliza un grupo NR3R4 o un grupo -N+CH3R3R4, o X e Y juntasforman un grupo-CH2-NR5, y Z representa un grupo >C=NH un grupo >CH2, R3 simboliza hidrogeno o un grupo alquilo inferior y R4 simboliza hidroxilo, carbamoilo,amidino, héteroarilo,N-aralquilhé teroarilo o un grupo alquilo inferior, o R3 y R4 juntas con el átomo de nitrogeno al cual se encuentran unidas forman unanillo heterocíclico que opcionalmente puede estar roto por un heteroátomo adicional y que opcionalmente puede estarsustituido un a o varia veces, R5representa hidrogeno, un grupo amidino o un héterociclo que opcionalmente se encuentra roto por uno o varios heteroátomos, para la produccion de preparadosfarmacéuticos con accion inhibitoria de la fosfolipasa, comoasí también los compuestos de formula (I), las sales, los ésteres, las formas opticamente activasy los racematos de los mismos fisiologicamente tolerados y también los derivados que se pueden metabolizar en vivo para formar compuestos de formulageneral(1), y los p reparados farmacéuticos que contienen a dichos compuestos de formula (1).Use of tetracycle derivatives [6.6.2.0 (2.7) .0 (9.14)] - hexadeca-2 (7), 3, 5, 9, (14), 10, 12-hexane of formula (1): characterized in that: R1 and R2 are identical or different and mean hydrogen or a halogen atom, X symbolizes hydrogen and Ysimb oliza an NR3R4 group or a group -N + CH3R3R4, or X and Y together form a group-CH2-NR5, and Z represents a group> C = NH a group> CH2, R3 symbolizes hydrogen or a lower alkyl group and R4 symbolizes hydroxyl, carbamoyl, amidino, heteroaryl, N-aralkyl teroaryl or a lower alkyl group, or R3 and R4 together with the nitrogen atom to which they are found together they form a heterocyclic ring that may optionally be broken by an additional heteroatom and that may optionally be substituted several years, R5 represents hydrogen, an amidino group or a heterocycle that is optionally broken by one or more heteroatoms, for the production of pharmaceutical preparations with action phospholipase inhibitor, as well Also compounds of formula (I), salts, esters, optically active forms and physiologically tolerated racemates thereof and also derivatives that can be metabolized in vivo to form compounds of general formula (1), and pharmaceutical preparations containing said compounds of formula (1).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19742014A DE19742014A1 (en) | 1997-09-24 | 1997-09-24 | Use of new and known tetracyclene compounds as phospholipase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
AR019256A1 true AR019256A1 (en) | 2002-02-13 |
Family
ID=7843387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980104764A AR019256A1 (en) | 1997-09-24 | 1998-09-23 | USE OF TETRACICLE DERIVATIVES [6-6-2-0 (2.27) .0 (9.14)] HEXADECA-2 (7), 3, 5, 9 (14), 10,12-HEXAENE, FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS CONACTION PHOSPHOLIPASE INHIBITORY, DERIVATIVE REFERRALS AND PHARMACEUTICAL PREPARATION CONTAINING AT LEAST ONE OF SUCH DERIVATIVES |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1034162A1 (en) |
JP (1) | JP2002505999A (en) |
KR (1) | KR20010024258A (en) |
CN (1) | CN1278789A (en) |
AR (1) | AR019256A1 (en) |
AU (1) | AU9746698A (en) |
BR (1) | BR9813217A (en) |
CA (1) | CA2304879A1 (en) |
DE (1) | DE19742014A1 (en) |
TR (1) | TR200001222T2 (en) |
WO (1) | WO1999015493A1 (en) |
ZA (1) | ZA988711B (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPS282602A0 (en) | 2002-06-07 | 2002-06-27 | Garvan Institute Of Medical Research | Method of inhibiting cell proliferation |
WO2004009017A2 (en) * | 2002-07-18 | 2004-01-29 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
US7253283B2 (en) | 2004-01-16 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US7273881B2 (en) | 2004-01-16 | 2007-09-25 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US7625921B2 (en) | 2004-01-16 | 2009-12-01 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US7605264B2 (en) * | 2004-01-16 | 2009-10-20 | Bristol-Myers Squibb Company | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US7569689B2 (en) * | 2004-01-16 | 2009-08-04 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US7326728B2 (en) | 2004-01-16 | 2008-02-05 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof |
US7361654B2 (en) | 2005-01-13 | 2008-04-22 | Bristol-Myers Squibb Co. | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US7317024B2 (en) | 2005-01-13 | 2008-01-08 | Bristol-Myers Squibb Co. | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US7411071B2 (en) | 2005-01-13 | 2008-08-12 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US7642273B2 (en) | 2005-01-13 | 2010-01-05 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US9498460B1 (en) | 2016-04-06 | 2016-11-22 | King Saud University | Halogenated tetracyclic compounds |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3123618A (en) * | 1964-03-03 | Io-dihydroanthkacene-z | ||
NL123295C (en) * | 1963-10-21 | |||
CH429711A (en) * | 1963-10-21 | 1967-02-15 | Geigy Ag J R | Process for the production of new ethanoanthracene derivatives |
CH426789A (en) * | 1963-10-21 | 1966-12-31 | Geigy Ag J R | Process for the production of new ethanoanthracene derivatives |
US3422104A (en) * | 1964-10-20 | 1969-01-14 | Geigy Chem Corp | 9,10-dihydro-11-amino-alkylene-9,10-ethanoanthracenes |
FR1459843A (en) * | 1965-07-27 | 1966-06-17 | Soc Ind Fab Antibiotiques Sifa | New quaternary ammonium salts derived from 9-ethano-9,10-dihydro-anthracene and method of preparation |
CH482642A (en) * | 1967-10-17 | 1969-12-15 | Geigy Ag J R | Process for the preparation of 11-aminoalkyl-9,10-dihydro-9,10-ethano-anthracenes |
US5039706A (en) * | 1987-11-30 | 1991-08-13 | Du Pont Merck Pharmaceutical Company | Antiinflammatory PLA2 inhibitors |
US5055468A (en) * | 1989-10-30 | 1991-10-08 | G. D. Searle & Co. | Use of bridged tricyclic amine derivatives as anti-ischemic agents |
US5409932A (en) * | 1993-12-09 | 1995-04-25 | Bayer Ag | Piperazine-substituted pyrroloanthracenes |
WO1995033715A1 (en) * | 1994-06-02 | 1995-12-14 | Smithkline Beecham Corporation | Anti-inflammatory compounds |
-
1997
- 1997-09-24 DE DE19742014A patent/DE19742014A1/en not_active Withdrawn
-
1998
- 1998-09-23 ZA ZA9808711A patent/ZA988711B/en unknown
- 1998-09-23 AR ARP980104764A patent/AR019256A1/en unknown
- 1998-09-24 CN CN98811160A patent/CN1278789A/en active Pending
- 1998-09-24 AU AU97466/98A patent/AU9746698A/en not_active Abandoned
- 1998-09-24 TR TR2000/01222T patent/TR200001222T2/en unknown
- 1998-09-24 CA CA002304879A patent/CA2304879A1/en not_active Abandoned
- 1998-09-24 WO PCT/EP1998/006096 patent/WO1999015493A1/en not_active Application Discontinuation
- 1998-09-24 JP JP2000512804A patent/JP2002505999A/en active Pending
- 1998-09-24 KR KR1020007003134A patent/KR20010024258A/en not_active Application Discontinuation
- 1998-09-24 EP EP98951464A patent/EP1034162A1/en not_active Withdrawn
- 1998-09-24 BR BR9813217-2A patent/BR9813217A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20010024258A (en) | 2001-03-26 |
DE19742014A1 (en) | 1999-03-25 |
BR9813217A (en) | 2000-08-29 |
EP1034162A1 (en) | 2000-09-13 |
CA2304879A1 (en) | 1999-04-01 |
TR200001222T2 (en) | 2000-09-21 |
AU9746698A (en) | 1999-04-12 |
JP2002505999A (en) | 2002-02-26 |
ZA988711B (en) | 2000-03-23 |
CN1278789A (en) | 2001-01-03 |
WO1999015493A8 (en) | 1999-05-06 |
WO1999015493A1 (en) | 1999-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR019256A1 (en) | USE OF TETRACICLE DERIVATIVES [6-6-2-0 (2.27) .0 (9.14)] HEXADECA-2 (7), 3, 5, 9 (14), 10,12-HEXAENE, FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS CONACTION PHOSPHOLIPASE INHIBITORY, DERIVATIVE REFERRALS AND PHARMACEUTICAL PREPARATION CONTAINING AT LEAST ONE OF SUCH DERIVATIVES | |
AR034253A1 (en) | GLUCOKINASE ACTIVATING COMPOUNDS CONTAINING REPLACED HYDANTOIN, A PROCEDURE FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS, PROCEDURES FOR THEIR PREPARATION, USE OF THE SAME FOR THE PREPARATION OF MEDICINES | |
AR033306A1 (en) | COMPOUNDS | |
AR068695A2 (en) | USE OF A TIAZOL COMPOUND THAT INCLUDES A TIAZOL DERIVATIVE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE PREVENTION AND TREATMENT OF DISEASES CAUSED BY THE NORMAL PRODUCTION OF CITOCINES AND / OR ACCELEATION OF THE ADHESION OF NEUTROPHILES AND / OR THE ABNORMAL PRODUCTION OF TNF-ALFA | |
PE20020566A1 (en) | DERIVATIVES OF PHENYLACETAMIDO-PYRAZOLES AS INHIBITORS OF cdk / CYCLINE KINASE | |
AR079541A1 (en) | SUBSTITUTED COMPOUNDS OF N- (1H-INDAZOL-4-IL) IMIDAZO (1,2-A) PIRIDIN-3-CARBOXAMIDE AS CFMS INHIBITORS | |
AR035417A1 (en) | TRICYCLE DERIVATIVES OF LACTAMA AND SULTAMA, PROCESSES FOR THEIR DEVELOPMENT, DRUGS THAT CONTAIN THEM, AND THE USE OF SUCH COMPOUNDS IN THE PREPARATION OF DRUGS | |
EA200200708A1 (en) | Derivatives of benzene and their use as modulators of JNK | |
DK0628311T3 (en) | Xanthine derivatives as antidepressants | |
HUP0000591A2 (en) | Piperazine, morpholine and thiomorpholine derivatives as metalloprotease inhibitors and use of them for producing pharmaceutical compositions | |
AR002690A1 (en) | DERIVATIVE OF BENCIMIDAZOLE OR SALTS OF THE SAME, PHARMACEUTICAL COMPOSITION, IMMUNOSUPPRESSIVE AGENT AND ANTI-INFLAMMATORY AGENT THAT CONTAIN IT AND PROCEDURES TO PREPARE SUCH DERIVATIVE. | |
ES2118203T3 (en) | NEW BENZOPYRANIC DERIVATIVES, THEIR PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
DK0437030T3 (en) | Use of 4-substituted imidazoles to reduce intraocular pressure | |
AR012436A1 (en) | 4-AMINOPIRIDE [2,3-D] PIRIMIDINE 5,7-DISSTITUTED COMPOUNDS, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, THE USE OF THE SAME FOR LAMANUFACTURE OF MEDICINES, A PROCEDURE FOR THEIR PREPARATION. | |
PT1216245E (en) | PHARMACEUTICALLY ACTIVE SULFONYL HYDROXIDE DERIVATIVES | |
AR055367A1 (en) | BICYCLE PIPERAZINS AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | |
AR018632A1 (en) | COMPOUNDS DERIVED FROM ACID 1,2,3,4-TETRAHYDROQUINOLIN-2-CARBOXILICO, ITS USE IN THE MANUFACTURE OF MEDICINES, PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCESS FOR PREPARATION. | |
SE9003973D0 (en) | GLYCEROL, A MANUFACTURING PROCEDURE FOR THE SAME AND THERAPEUTIC COMPOSITIONS CONTAINING THEM | |
AR036734A1 (en) | DERIVATIVES OF 8-AMINO- [1,2,4] TRIAZOLO [1,5-A] PIRIDINA-6-CARBOXILICO | |
MX9405111A (en) | NEW DERIVATIVES OF (1-PHENYL-1-HETEROCICLIL) METHANOL AND (1-PHENYL-1-HETEROCICLIL-METHYLAMINE). | |
AR027454A1 (en) | DERIVATIVES OF BETA-ALANINA, USEFUL AS RECEIVER ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE USE OF THEM FOR THE PREPARATION OF MEDICINES | |
AR039008A1 (en) | AZABICICLIC, AZATRICICLIC AND AZAESPIROCICLIC DERIVATIVES OF AMINOCICLOHEXAN ANTAGONISTS OF NMDA, 5-HT3, AND NEURONAL NICOTINIC RECEPTORS | |
ES2057415T3 (en) | BICYCLE DERIVATIVES. | |
AR031168A1 (en) | DERIVATIVES OF INDOLILPIPERIDINE AS ANTIHISTAMINIC AND ANTIALERGIC AGENTS | |
ES2037758T3 (en) | A METHOD OF USE OF A CHINOLINCARBOXYLIC DERIVATIVE AND ITS PREPARATION PROCEDURE. |